272 related articles for article (PubMed ID: 19844750)
1. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
Punekar YS; Hawkins N
Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
[TBL] [Abstract][Full Text] [Related]
2. Infliximab for the treatment of acute exacerbations of ulcerative colitis.
Bryan S; Andronis L; Hyde C; Connock M; Fry-Smith A; Wang D
Health Technol Assess; 2010 May; 14 Suppl 1():9-15. PubMed ID: 20507798
[TBL] [Abstract][Full Text] [Related]
3. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
4. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT).
Williams JG; Alam MF; Alrubaiy L; Clement C; Cohen D; Grey M; Hilton M; Hutchings HA; Longo M; Morgan JM; Rapport FL; Seagrove AC; Watkins A
Health Technol Assess; 2016 Jun; 20(44):1-320. PubMed ID: 27329657
[TBL] [Abstract][Full Text] [Related]
5. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
7. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.
Tsai HH; Punekar YS; Morris J; Fortun P
Aliment Pharmacol Ther; 2008 Nov; 28(10):1230-9. PubMed ID: 18729845
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT).
Seagrove AC; Alam MF; Alrubaiy L; Cheung WY; Clement C; Cohen D; Grey M; Hilton M; Hutchings H; Morgan J; Rapport F; Roberts SE; Russell D; Russell I; Thomas L; Thorne K; Watkins A; Williams JG
BMJ Open; 2014 Apr; 4(4):e005091. PubMed ID: 24785401
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.
Park KT; Perez F; Tsai R; Honkanen A; Bass D; Garber A
J Pediatr Gastroenterol Nutr; 2011 Nov; 53(5):489-96. PubMed ID: 21694634
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of early colectomy with ileal pouch-anal anastamosis versus standard medical therapy in severe ulcerative colitis.
Park KT; Tsai R; Perez F; Cipriano LE; Bass D; Garber AM
Ann Surg; 2012 Jul; 256(1):117-24. PubMed ID: 22270693
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of ulcerative colitis.
Hyde C; Bryan S; Juarez-Garcia A; Andronis L; Fry-Smith A
Health Technol Assess; 2009 Oct; 13 Suppl 3():7-11. PubMed ID: 19846023
[TBL] [Abstract][Full Text] [Related]
12. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.
Williams JG; Alam MF; Alrubaiy L; Arnott I; Clement C; Cohen D; Gordon JN; Hawthorne AB; Hilton M; Hutchings HA; Jawhari AU; Longo M; Mansfield J; Morgan JM; Rapport F; Seagrove AC; Sebastian S; Shaw I; Travis SP; Watkins A
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):15-24. PubMed ID: 27595142
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab.
Croft A; Walsh A; Doecke J; Cooley R; Howlett M; Radford-Smith G
Aliment Pharmacol Ther; 2013 Aug; 38(3):294-302. PubMed ID: 23786158
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Wu B; Wang Z; Zhang Q
Inflamm Bowel Dis; 2018 Oct; 24(11):2291-2302. PubMed ID: 29718241
[TBL] [Abstract][Full Text] [Related]
15. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
Stawowczyk E; Kawalec P; Pilc A
Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.
Punekar YS; Sunderland T; Hawkins N; Lindsay J
Value Health; 2010; 13(2):188-95. PubMed ID: 19883407
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
20. Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis.
Ung V; Thanh NX; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Fedorak RN
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1871-8.e8. PubMed ID: 24674943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
